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3mT001 
 
Insights in POLYpharmacy MAnagement 
(INPOLYMA) of DOAC patients – preliminary results 
 
Valerie ALBERT, Ramona HAAG, Kurt E. HERSBERGER, 
Isabelle ARNET 
Background 
A high number of medication makes their management difficult 
and may negatively influence adherence to medication. With direct 
oral anticoagulants (DOAC), timing adherence is especially crucial 
because these agents have a short duration of action. Many 
patients develop own management strategies to cope with 
polypharmacy and health care professionals need to know how 
patients manage the daily intake of several medications. 
Purpose  
In order to offer the best pharmaceutical care to patients with 
polypharmacy, our objective is to assess patients’ management of 
polypharmacy in general and DOAC medication in particular in real 
life setting.  
Methods 
This is a qualitative study recruiting 15 outpatients through flyers 
in Switzerland. Patients are independently taking at least four 
medications (including DOAC) since three or more months. During 
home visits, insights in self-management are gathered with 
qualitative in-depth interviews (recorded, transcribed verbatim). 
Interviews are analysed with MAXQDA to find similarities, 
differences and reasons for specific management strategies. 
Relationship between knowledge about DOAC and actual 
adherence will be investigated by means of questionnaires and a 
small electronic device (Time4MedTM) that registers the 
timepoints of medication intake during one month.  
Results  
The study started on February 12, 2018 and seven patients (age 
77-95) have been recruited until now. Intake of medication 
occurred twice to five times daily. Most patients used a 
multicompartment compliance aid. All patients coupled the times 
of medication intake with meals and stored the medication in a 
visible place such as the kitchen table. For some patients specific 
medication was more important and therefore taken more 
consciously than other was. 
Conclusions 
This observational study will provide insights in patients’ 
management of their multiple medications. The preliminary results 
indicate that some management strategies are questionable. The 
insights gained through interviews will give valuable information 
for the development of pharmaceutical care interventions. 
 
 
3mT002 
Medicines-related readmissions: Targeted 
intervention delivery 
 
V-Lin CHEONG, Jonathan SILCOCK, Julie SOWTER,  
Neil HAMILTON 
Background 
Readmission to hospital is prevalent in the older population, and 
can affect patients’ quality of life [1, 2]. Evidence suggests that 
better transition-of-care can reduce hospital admission rates and 
health expenditure [3]. It was estimated that medication-related 
problems account for approximately 40% of readmissions [4]. Little 
is known about the medicines-related predictors of readmission in 
the frail elderly population. Further understanding of predictors of 
readmission would help identify patients with the greatest risk of 
readmissions; who would benefit most from high-intensity 
interventions [5].  
Purpose 
The objectives of the PhD thesis were to identify medicines-related 
risks associated with readmission, and the pharmaceutical 
interventions effective at reducing readmissions. These would 
facilitate the design of interventions targeted for frail elderly 
patients at risk of medicines-related readmission. 
Methods 
A case-control design study was conducted to examine the 
association of medicines-related risks such as polypharmacy and 
potentially inappropriate medicines (PIMs) with readmission. Next, 
systematic review of the pharmaceutical interventions aimed at 
reducing readmissions was carried out to identify effective 
interventions. Then, a Delphi study was done to establish the 
priority interventions of clinicians, patients/carers. These 
facilitated the design of prioritised evidence-based interventions, 
to be delivered to patients with readmission risks. 
Results 
It was found that PIM use, alongside polypharmacy (≥10 
medicines) among other risks were associated with readmission in 
older patients. However, medicines-related risks were not 
predictive of readmission after adjusting for confounders. 
Pharmaceutical interventions which were effective were mainly 
based on improving communication between clinicians and 
patients. Interventions prioritisation by clinicians and patients are 
currently investigated. 
Conclusions 
Medicines-related risk factors may be included in future risk 
models to examine its predictive effects. Involving patients and 
clinicians to prioritise evidence-based interventions is important 
for person-centred care service design. 
 
 
3mT003 
 
A review of healthcare professionals’ knowledge 
and perspectives regarding substandard and 
falsified antimicrobials 
 
Naira GHANEM, Oksana PYZIK, Victoria RUTTER, Nadia 
BUKHARI 
Background 
Current literature discusses prevalence rates, technologies for 
detection and outcomes of low-quality medicines. There is a 
reduced emphasis on the importance of healthcare professionals 
awareness of issues and the difference in societies and which 
interventions will be the most effective.  
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Purpose 
This study aims to measure healthcare professionals’ ‘knowledge 
of’, ‘exposure to’ and ‘attitudes towards’ substandard and falsified 
antimicrobials 
Methods 
A cross-sectional study was used to assess healthcare 
professionals’ (HCPs) perspectives in high-income countries (HICs) 
and low-middle income countries (LMICs). The study used 
convenience sampling through distribution channels via the 
Commonwealth Pharmacy Association (CPA). 
Results 
A total of 256 healthcare professionals took part in the study from 
six regions worldwide. 54% of the participants were aware of the 
difference between a substandard and falsified antimicrobial. The 
most prevalent definitions for a substandard antimicrobial was a 
medicine with a ‘lower Active Pharmaceutical Ingredient (API) 
content’ (67%). The most prevalent definition for a falsified 
antimicrobial was a ‘counterfeit medicine’ (78%). Healthcare 
professionals from African and Asian LMICs had the highest rates 
of correctly identifying substandard and falsified antimicrobials. 
Healthcare professionals’ attitudes towards preventative methods 
to combat falsified antimicrobials were reflective of the problems 
in each region.  
Conclusions 
Preventative methods such as ‘raising public awareness’ and 
‘educating HCPs’ were ranked highly in the UK. In comparison, 
healthcare professionals from African LMICs supported ‘improved 
reporting methods’, ‘detection methods’ and a ‘tighter, regulated 
supply chain’. The different weighting given to preventative 
methods according to economic classification further emphasizes 
that no ‘one size fits all’ approach can be used to effectively tackle 
this issue. More comprehensive insight is needed, relative to 
regions and economic status to determine the best approach to 
tackle this global problem in a localised manner. 
 
 
3mT004 
 
Community pharmacist perspectives on 
opportunities to develop their role in breast cancer 
services 
 
Lydia TUTT, Tracey THORNLEY, Li-Chia CHEN,  
Claire ANDERSON 
Background  
Breast cancer is the most common cancer in the UK. Improving 
survival rates coupled with long-term treatment requirements 
have created demand for primary care-based services to support 
survivors. Community pharmacists therefore have scope to take on 
a more significant role. 
Purpose  
The purpose of this study was to investigate community 
pharmacist perspectives on developing services to better support 
breast cancer survivors and to explore potential opportunities and 
barriers surrounding survivor-reported care needs.  
Methods 
Online focus groups were conducted with community pharmacists 
from across England. Eligible participants were those currently 
practising within England. The topic guide contained themes 
derived from a previous study, which used focus groups to explore 
breast cancer survivor experiences in primary care. Transcripts 
from the web-based chat were analysed using iterative thematic 
analysis.   
Results  
Two focus groups were conducted (9 participants in total). Themes 
for supporting survivors included: Appropriate signposting; 
providing the right information at the right time; advising on 
suitable pharmacy products; promoting pharmacist roles and 
services; collaborating with other healthcare providers and local 
support services; and undertaking further training. Pharmacists 
acknowledged barriers such as time and funding but were keen to 
provide support as part of existing services such as Medicines Use 
Reviews or Healthy Living Pharmacy campaigns. 
Conclusions 
Findings provide insight into how community pharmacists feel they 
could improve care for breast cancer survivors. Findings highlight 
many small changes that pharmacists could make within their 
current practice; including training, networking, and proactively 
having conversations with survivors. Going forward, these findings 
can also be used by those involved in healthcare service 
development and policy-making to inform the design of services or 
interventions. This research was part of a more extensive mixed 
methods study to explore the role of the community pharmacist in 
breast cancer services. Future work will investigate the 
perspectives of key stakeholders on these findings. 
 
 
3mT005 
 
Evaluation of medication costs for patients referred 
to an internal medicine pharmacist clinic in Canada 
 
Eric LANDRY, Katherine LYSAK, Derek JORGENSON 
Background 
A referral-based system of pharmacist specialists could be useful in 
assisting community/hospital pharmacists to manage complex 
patients. The University of Saskatchewan College of Pharmacy and 
Nutrition recently opened the Medication Assessment Centre 
(MAC), which accepts complex general medicine referrals and 
which considers itself an internal medicine pharmacist specialist 
clinic. The MAC is also used as an experiential learning rotation for 
undergraduate pharmacy students. This internal medicine 
pharmacist clinic model has not been previously evaluated and its 
impact on medication costs is relevant to health system decision 
makers. 
Purpose 
To evaluate the impact of referral to the MAC on patients’ monthly 
medication costs.  
Methods 
Retrospective chart review. Patients who had been referred to the 
MAC and who had completed an assessment between May 2016 
and March 2017 were eligible. Baseline monthly costs were 
calculated using initial medication lists, which included 
prescription, non-prescription and natural medicines. The baseline 
cost was compared to patient’s final medication list, which was 
established at least one month after the initial visit, when 
recommendations for adjustments had been communicated to 
prescribers. Medication changes that were not directly attributed 
to recommendations made by the pharmacist were not included in 
the analysis. Prescription drug costs were calculated using prices 
from the Saskatchewan formulary and retail prices from an online 
Canadian retailer were used to calculate non-prescription/natural 
medicine costs.      
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Results 
A total of 53 charts were included. Mean monthly medication costs 
(prescription, non-prescription, natural medicines combined) were 
$24.17 lower per patient after the pharmacist assessment had 
been completed ($371.00 per month vs. $346.83 per month, 
p=0.02).  
Conclusions 
Patients who are referred to this internal medicine pharmacist 
specialist clinic have lower overall drug costs after consultation 
with the pharmacist. 
 
 
3mT006 
 
A contribution to the economic evaluation of 
pharmacy services in a collaborative care model in 
Portugal 
 
Suzete COSTA, João PEREIRA, Dennis K HELLING,  
Maria CARY, Céu MATEUS 
Background 
The economic evaluation of public health interventions provided 
by pharmacists in collaborative environments with physicians may 
contribute to inform decisions in the successful expansion, 
continuation, or justification of such services. This project uses a 
collaborative experiment between NHS primary care and local 
pharmacies comprising intervention protocols in pharmacy 
software that interact with physicians’ software and regular quality 
circles (physicians, nurses and pharmacists). 
Purpose 
To explore tools and methods of economic evaluations and 
understand whether a pharmacy-driven collaborative intervention 
with primary care, in selected interventions under protocol, can be 
cost-effective vs. usual care. 
Methods 
1) Overview of systematic reviews of economic evaluations of 
pharmacy-based public health interventions to address 
methodological challenges; 2) Review of evidence of selected 
interventions under collaborative care; 3) Effectiveness and 
economic evaluation of a collaborative pharmacy-based 
hypertension and/or hyperlipidaemia management alongside a 
pragmatic controlled trial. Outcome measures: changes in blood 
pressure, cholesterol, cardiovascular risk, adherence, persistence, 
quality-of-life, patient preferences. Cost data: medical and 
pharmacy appointments, point-of-care, medication, patient travel 
time/transport, absenteeism, emergency room and hospital 
admissions. Data sources: pharmacy software; primary care 
software; patient telephone surveys.  
Results 
1) presented in a separate abstract; 2) ongoing; 3) 8 preparatory 
workshops + 2 training sessions for pharmacies and 6 quality 
circles. The pilot started on 27 April 2018 (time of abstract 
submission). 
Conclusions 
We hope to contribute to: developing a feasible system for 
measurement and valuation of costs and consequences of 
pharmacy interventions; improving methods and tools for the 
economic evaluations of pharmacy and public health interventions; 
increasing evidence on the effectiveness and value of pharmacy 
interventions under collaborative practice with primary care; 
advancing standards of care and raising questions on the role of 
complementary payment models of healthcare providers. 
 
 
3mT007 
 
Initial review on software tools to evaluate package 
leaflets of medicines 
 
Carla PIRES, Afonso M. CAVACO 
Background 
Package leaflets of medicines (PLs) are compulsory inside all 
packages of medicines within the European Union market. PLs 
serve to inform medicines users, although PLs’ readability issues do 
exist. It is not known the extent to which software tools, designed 
to automatically assess texts features, have been used to study 
legibility and content of PLs. 
Purpose 
To identify and examine published studies describing the use of 
software tools for analyzing, processing, extracting or simplifying 
information specifically from PLs, particularly those written in 
Portuguese. 
Methods 
PubMed, Cochrane Library, and SciELO literature databases were 
searched, without time restrictions, using the expressions: 
“software” and (“package inserts” or “package leaflets” or 
“summary of product characteristics” or “bulas”/“folhetos” – 
Portuguese designations of PLs) in March 2018. Studies reporting 
software tools for analyzing, simplifying, processing or extracting 
information from PLs were included. The Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
checklist and flow diagram were applied. The study results were 
doubled checked. 
Results 
From the 154 identified studies, 143 were excluded because they 
did not comply with the inclusion criteria, being 4 repeated. From 
the 7 selected studies, 3 comprised software applications that 
evaluate text features, while 4 the extraction, collection, and 
classification of information from PLs. One software application 
was found for Portuguese language to count words and identify 
abbreviations.  
Conclusions 
Software tools to evaluate and/or process information or legibility 
features of PLs seem to be limited, suggesting the need of 
development of applications in this area. Further searches might 
be needed to improve the robustness of the present findings. 
Future tools should consider different languages/cultural 
backgrounds, as well be capable of automatically optimizing 
therapeutic information and patient counselling key sentences. 
 
 
3mT008 
 
Project PRIMA – Implementation of the German 
National Medication Plan from community 
pharmacists` and physicians` perspective 
 
Ann K. STRUNZ, Uta MÜLLER, Christiane EICKHOFF,  
Hanna M. SEIDLING, Anette LAMPERT, Miriam FELBERG, 
Sabine Breiholz, Dirk KLINTWORTH, Martin SCHULZ 
3-minute thesis. Pharmacy Practice 2018 Jun;16(Suppl1):1339.  
https://doi.org/10.18549/PharmPract.2018.s1.1339 
www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X) 4 
Background 
In the project PRIMA an interdisciplinary medication management 
(MM) service was offered by physicians (GPs) and community 
pharmacists (CPs). To exchange information on patients’ 
medication and potential drug-related problems, a standardized 
medication plan (MP) was generated in the local software systems 
of both health care professionals (HCPs), exchanged via a central 
server and subsequently printed for the patient.  
Purpose 
The primary aim of PRIMA was to evaluate the acceptance of the 
processes in the MM service and the MP by the participating HCPs.  
Methods 
PRIMA was conducted from October 2014 to December 2016 
involving 12 teams of each one CPs and GPs to generate and 
update MPs according to previously specified processes and 
responsibilities [1]. HCPs operated in their local software 
applications and exchanged MPs via a central server.  
Questionnaires were developed to evaluate the HCP’s acceptance 
of the MM service. Additionally, HCPs participated in a workshop in 
September 2016 to discuss their experiences regarding 
collaboration, communication and benefits of the MM service for 
their patients. 
Results 
Of the 12 teams of CPs and GPs one dropped out due to technical 
problems. The remaining 11 teams recruited 196 patients. In total, 
35 HCPs participated in the workshop. HCPs named improvement 
of medication safety as their major motivation to participate 
(83.3%, n=18). 75.0% (n=8) of the pharmacists and 60.0% (n=10) of 
the physicians agreed with the previously specified processes and 
responsibilities in the MM service. HCPs estimated that the service 
improved the implementation of drug therapy (83.3 %, n=24) and 
appropriateness of medication (78.6%, n=28). Furthermore, HCPs 
expected a reduction in overall health-related costs (82.1%, n=28). 
Conclusions 
The electronic MP as well as the MM service were successfully 
implemented and accepted by the HCPs. This is an important 
precondition to further implement both the MM service and the 
MP in primary care in Germany. 
 
 
3mT009 
 
Methodological approach to health economic 
analysis of pharmacists’ interventions on 
prescriptions in community pharmacies 
 
Eirin G. ROBINSON, Janne SMEDBERG,  
Ingunn BJÖRNSDOTTIR 
Background 
In community pharmacies, substantial resources are used on 
interventions on prescriptions in the dispensing process in order to 
contribute to appropriate and safe use of medication. Data from 
42 pharmacies on 39,864 dispensing processes for more than 
70,000 individual drugs was collected by the Norwegian Pharmacy 
Association. The prescription errors uncovered, the interventions 
performed, and the time invested can be analyzed in terms of how 
much has been invested in interventions. A full health economic 
analysis, taking outcomes into account, is desirable, but data on 
outcomes have not been registered. 
Purpose 
The objective of this study was to find a suitable method to collect 
and evaluate health outcomes data.  
Methods 
Published literature was reviewed in search for an appropriate 
method to collect health outcomes data in a pharmacy practice 
setting. 
Results 
We have identified different instruments to record and scale 
clinical significance of prescription errors and acceptability of 
intervention. Most of these methods have been used in a hospital 
setting, and must be adjusted to fit in a community pharmacy 
setting. No single publication comprised one suitable method for 
our purpose, but it may be possible to combine elements from 
several methods. 
Conclusions 
There is a need to develop a suitable method to collect and 
evaluate health outcomes data for a health economic evaluation of 
community pharmacists’ interventions on prescriptions. The 
articles reviewed may form the basis for developing a method. 
 
 
3mT010 
 
AMBER study -an algorithm-based tool for 
Medication Management in nursing homes 
 
Susanne ERZKAMP, Olaf ROSE 
Background 
Medication regimes of nursing home residents can be complex and 
challenging. Daily workload hampers advanced patient centred 
care in many cases. Even though clinical pharmacy services can 
improve the quality of drug therapy, they are rarely established in 
routine care. Focusing on frequent and relevant problems might be 
a facilitator to overcome the barriers. 
Purpose 
To support pharmacists in performing a structured and feasible 
Medication Review in nursing homes, in an appropriate timeframe, 
an algorithm is developed and evaluated.  
Methods 
The study consists of 3 phases and is registered at the German 
Clinical Trial Register (DRKS00010995). In phase I, semi-structured 
interviews are performed with healthcare practitioners and 
patients to determine frequent and relevant problems in the 
medication process in nursing homes. In phase IIa, a systematic 
review is performed, following PRISMA-P 2015. Quality of 
reporting is assessed using the AMSTAR and TIDieR checklists. 
Considering the results of phase I and IIa, summarised aspects are 
presented to a Delphi expert panel in phase IIb. The algorithm is 
adjusted and tested for practicability and effectiveness in phase III 
in an open, single arm, interventional study. The study protocol 
follows the SPIRIT 2013 statement. The primary outcome of phase 
III is the reduction of drug-related problems, which are detected 
using the tool, and classified according to PCNE V.8.02. Feasibility 
and reproducibility will be tested. 
Results 
The results of phase I-IIb led to a preliminary algorithm with 10 
steps. It covers for example: chief complaints, interactions, 
potentially inappropriate medication and medication without 
indication. First results of phase III are expected in 05/18.  
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Conclusions  
The developed algorithm-based tool for Medication Review 
considers aspects of clinical practice, clinical experience, best 
available evidence and expert opinions. Currently, the tool is 
tested in several nursing homes. 
 
 
3mT011 
 
Use of medication dispensing records to measure 
the effect of pharmacist interventions on 
medication adherence in a community pharmacy 
setting 
 
Andrea TORRES-ROBLES, Barry DRAKE,  
Shalom I. BENRIMOJ, Victoria GARCIA-CARDENAS 
Background 
Pharmacy GuildLink (http://www.guildlink.com.au/) is a company 
that provides software packages and education to community 
pharmacies. They also offer a number of adherence programs that 
outline interventions for specific molecules. Pharmacist are alerted 
to potential non-adherence through use of the Medindex score 
and directed to a protocol for intervention. The programs use 
medication-dispensing records for primary analysis. The amount 
and complexity of data recorded on community pharmacies 
require Big data techniques and analytics to determine the effects 
on medication adherence.  
Purpose 
To analyse the impact of a pharmacist intervention on medication 
adherence in patients using rosuvastatin, irbesartan and/or 
desvenlafaxine by analysing dispensing data.  
Methods 
A big data set containing records of 2630201 patients from 
community pharmacies in Australia was organized and validated by 
using SQL and Python. Patients included in the analysis received an 
intervention by the community pharmacist and had to be using 
rosuvastatin, irbesartan and/or desvenlafaxine, with at least 2 
dispensings before and after the first intervention. Key indicators 
used were Proportion of days covered (PDC) and Medication 
Possession Ratio.   
Results 
Dispensing data of 18687 patients were analysed (10425 for 
rosuvastatin, 6214 for irbesartan, 2048 for desvenlafaxine). An 
increase on PDC after the intervention was observed for all three 
groups of patients: 15.9%, 16.3%, 18.1%.  A decrease on adherence 
rates during the 12 months post intervention was observed: of 
7.9%, 9.2%, and 10.9% respectively.  
Conclusions 
The pharmacist intervention resulted on an increase of average 
adherence for all the patients that gradually declines over 12 
months. Results suggest that, as adherence drops over time, 
continuous and enhanced interventions are necessary to not only 
improve but also maintain adherence over time. Big data is a 
potential resource to analyse adherence in community 
pharmacies. 
 
 
3mT012 
 
Pharmacotherapeutic follow-up of outpatients with 
rheumatoid arthritis in teaching hospital: process 
and outcomes evaluation 
 
Bruna E. OLIVEIRA, Valeska Q. CASTRO, Marta M. FREITAS, 
José G. PAIVA, Sheila M. FONTENELE,  
Mirian P. MONTEIRO, Marta M. FONTELES  
Background 
The implementation of clinical pharmacy services in Brazil's public 
health system faces challenges that go beyond national regulatory 
advances and international recommendations, such as the need to 
study and apply measurable effectiveness indicators, harmonized 
with an administrative and social vision.Thus, research service is 
shown up as a possible method for the evaluation of these services 
in the country, through the critical and reflexive investigation of 
the practice, in line with the clinical-humanistic paradigm.  
Purpose 
To evaluate the quality of the pharmacotherapeutic follow-up 
service (PTF) of outpatients with rheumatoid arthritis (RA), as well 
as its potential for implementation in a real-world situation.  
Methods 
Descriptive, longitudinal and prospective research, which is in the 
methodological detailing phase, with a perspective of quantitative-
qualitative approach, and will be held in the outpatient pharmacy 
of a teaching hospital. An initial phase of awareness among the 
professionals involved (physicians, nurses and pharmacists) has 
been performed. The PTF service will be evaluated through 
implementation indicators used as intermediate process indicators 
in relation to the service, clinical and humanistic outcomes. For 
twelve month follow-up, outpatients will be attended by the 
pharmacist using the Dader method. The process indicators related 
to the service to be evaluated: relevance, acceptability, feasibility 
and fidelity. The process indicators related to clinical and 
humanistic outcomes to be evaluated: drug-related problems, 
pharmaceutical interventions with the patient and health 
professionals, adherence to treatment, quality of life and patient 
satisfaction. This research project is part of a larger project, 
prepared by the Pharmacy Department in partnership with the 
University Hospital's Ambulatory Pharmacy, whose pilot study has 
been developed. Ethical issues were considered and the research 
was promptly approved by the Research Ethics Committee of the 
Federal University of Ceará-Brazil. 
 
 
3mT013 
 
Medication information received from general 
practitioners and pharmacies – a cross-sectional 
questionnaire study 
 
Elisabeth PEDERSEN, Beate H. GARCIA,  
Kjell H. HALVORSEN, Anne E. EGGEN, Marit WAASETH 
Background 
Information about medicines is important to encourage adherence 
in patients but both pharmacists and physicians struggle to meet 
patients’ information needs.  
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Purpose 
To compare patients’ perceptions of which medication information 
they have received from general practitioners (GPs) and 
pharmacies. 
Methods 
We conducted a cross-sectional study using questionnaire data 
from the seventh wave of the Tromsø Study. This population-based 
health survey was conducted in 2015-16, inviting all inhabitants in 
the municipality of Tromsø, Norway, aged ≥ 40 years.  We included 
all participants reporting regular medication use (n= 10406). 
Participants rated their agreement to eight statements on whether 
they had received medication information from GPs and 
pharmacies regarding indication, administration, side effects and 
interactions. Agreement was measured by Likert-scale ranging 
from 1 (strongly disagree) to 5 (strongly agree). Pairwise t-tests 
were conducted to explore the difference between GPs and 
pharmacies, overall and within selected disease and medication 
groups. 
Results 
Indication was the highest rated information category for GPs (92% 
agreed), while administration was the highest rated information 
category for pharmacies (78% agreed).  Interactions was the lowest 
rated information category for both GPs (47% agreed) and 
pharmacies (47% agreed).  Participants had a significantly higher 
agreement to receiving information from GPs than from 
pharmacies on all four categories, measured by mean difference in 
Likert score (SD): indication 0.835 (1.383), administration 0.395 
(1.162), side effects 0.178 (1.229) and interactions 0.070 (1.177). 
Results were similar across all disease groups and most medication 
groups. 
Conclusions 
Patients seem to receive medication information to a greater 
extent from GPs than from pharmacies, particularly regarding 
indication, but also regarding administration, side effects and 
interactions. Further analyses will be conducted to investigate 
whether medication information received is associated with 
adherence or treatment goal achievements. 
 
 
3mT014 
 
Pharmaceutical regulation, policy and access to 
medicines 
 
Lilian WISMAYER, Maurice  ZARB-ADAMI,  
Chiara SCERRI HERRERA, Martina MUSCAT 
Background 
Access to appropriate medication is a multi-faceted issue which, 
unless properly understood and managed, has the potential for 
grave repercussions to public health. Significant pan-European 
disparities in this area have highlighted the need for research, 
which should provide a better elucidation of determinants with the 
potential to influence outcomes. 
Purpose 
It cannot be acceptable to witness gaps in addressing disease, 
which could be remedied by more coherent policies. This study, 
therefore, sought to identify a relationship between 
pharmaceutical policy, the regulatory infrastructure and access to 
medicines. 
Methods 
With this scope, a thorough and in-depth literature review was 
combined with methodological triangulation designed to gather 
qualitative and quantitative data. This included both structured 
and semi-structured interviews with policy-makers, regulators and 
healthcare professionals, as well as structured questionnaires to 
medical doctors and pharmacists.  
Results 
Initial results demonstrate that policy decisions produce disparate 
levels of access across the European Union (EU), most notably to 
innovative medication. Member states differ in the way they apply 
Health Technology Assessments with repercussions to the 
spectrum of medicines available on national health systems. 
Regulatory legislation, aiming to ensure appropriate standards of 
quality, safety and efficacy of medicinal products, may have the 
undesired aftermath of reducing access, particularly in the smaller 
member states. 
Conclusions 
This preliminary study, which is part of a wider research, suggests 
that barriers to medicines’ access are interconnected to 
pharmaceutical policy, the regulatory framework, and to market 
characteristics. It is deplorable that patients in the European Union 
today do not enjoy equal access to medicines, generally 
acknowledged as a patient right. Further research is planned to 
identify and evaluate factors which impact on access and to 
propose harmonised and sustainable methodologies that provide a 
common decision-making platform to all member states. 
 
 
3mT015 
 
Pharmacists bridging the gap: Hospital- and 
community pharmacists’ view on transitional care 
issues 
 
Laura V. JEDIG LECH, Anna B. ALMARSDÓTTIR,  
Lotte S. NØRGAARD, Trine R. NIELSEN, Charlotte ROSSING 
Background 
Transition of care from hospital to patient’s own home introduces 
risks, such as loss of medical information. Studies have shown that 
interventions involving pharmacists can aid in seamless transition 
of patients. However, fewer studies have focused on pharmacists’ 
beliefs and attitudes towards interventions to improve the 
discharge process. 
Purpose 
To identify problems and possible solutions and to gather 
suggestions for a collaborative intervention for seamless care 
involving hospital and community pharmacists in the transition 
from hospital to home.  
Methods 
Hospital and community pharmacists from the Region Zealand, 
Denmark were invited to participate in two focus group interviews. 
The focus groups were conducted using a dynamic interview guide 
with a moderator and an experienced facilitator.   
Results 
The focus groups were conducted in June 2017 and consisted of 4 
and 7 pharmacists, respectively. The pharmacists identified 
problems and solutions in three themes; Communication, 
Collaboration and Administration. The solutions were mainly 
related to IT -systems, establishing a transition “manager”, 
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granting access to more information and to a greater extent, 
informing other professionals about the experienced problems. 
The pharmacists were positive towards a cross-sectorial 
collaboration and identified topics such as compliance and better 
referral to existing services on the community pharmacy. 
Pharmacists suggested that a collaborative intervention should 
secure clinical relevance of the pharmacists’ work, be 
interdisciplinary and should be distinguished from existing 
pharmacist services.  
Conclusions 
Pharmacists identified transitional problems related to 
communication, collaboration and administration at the discharge 
stage. Solutions to some of these problems were related to access 
and dissemination of information and IT systems. Pharmacists 
identified several areas where collaboration of pharmacists across 
sectors could benefit patients and address hospital discharge 
problems. 
 
 
3mT016 
 
Nature and frequency of interventions and 
counselling provided in community pharmacies in 
Norway 
 
Hilde ARIANSEN, Stine W. RØNNINGEN, Ragnar HOVLAND, 
Janne SMEDBERG 
Background 
How do pharmacies supply added value to the community and the 
individual customers in addition to the actual dispensing process? 
Purpose 
The purpose of the study was to assess the nature and frequency 
of interventions and counselling provided during the dispensing 
process.  
Methods 
The pharmacy staff in 42 pharmacies reported predefined events, 
interventions and cases of counselling immediately after each 
dispensing process.  
Results 
The pharmacies reported events from 39 864 dispensing 
processes. The drug was not inaccessible in 5.5% of the processes 
and the prescription contained errors/deficiencies in 3.4%. The 
pharmacies handled interactions, contraindications, side effects, 
allergies and duplicate prescriptions in 3.1% of the processes. The 
most frequent intervention was talking to the patients. Invalid 
prescription was the most frequent reason for consulting 
prescribers. Average consultation time was 6.7 minutes, equally 
distributed between waiting time and dialogue. Counselling was 
provided in 60% of the processes and was most often about 
contributing appropriate use of the medication. 
Conclusions 
In community pharmacies, substantial resources are put into 
performing interventions and providing counselling, to ensure that 
patients receive safe and effective therapy. The study uncovers the 
need for health economic evaluation of these interventions. 
 
 
3mT017 
Can a two-way automated patient contact 
intervention improve adherence to medicines? A 
systematic review 
 
Gemma DONOVAN, Nicolla HALL, Felicity SMITH, Jonathan 
LING, Scott WILKES 
Background 
Around half of medications for long term conditions (LTCs) are not 
taken by patients as directed. Text messaging (TM) and Interactive 
Voice Response (IVR) technology (communication via voice 
recognition or keypad input) are both currently used for a variety 
of health purposes. Software for both of these mediums can 
automate delivery of messages and respond to patient input, 
making this technology efficient.  
Purpose 
To discover if two-way automated TM or IVR patient contact 
interventions can support medication adherence. 
Methods 
This narrative synthesis systematic review included studies 
focussing on adults self-caring for LTCs. Automated TM or IVR to 
improve medicines adherence must have been the primary 
intervention. Only studies conducted in high income countries 
were included. Pilot and feasibility studies were excluded. A 
comprehensive search of healthcare databases was conducted. 
Outcomes of interest were adherence to medicines, clinical 
condition control and patient acceptability. Data was extracted 
around study characteristics, intervention design and intervention 
delivery. Two researchers (GD and NH) were involved in screening 
and data extraction.  
Results 
43 papers were included covering 37 studies. Most studies were 
randomised controlled trials (n=25) and conducted in the United 
States (n=30). 19 used IVR, 10 TM, 2 pager devices and 5 used a 
combination. LTCs included diabetes (n=8), cardiovascular disease 
(n=7), hypertension (n=5) and HIV/ AIDS (n=5). Where studied, 70% 
found an improvement in medication adherence, 55% in clinical 
outcomes and 79% reported positive patient experience. Only 7 
studies included findings from all three outcomes of interest. 
Conclusions 
Two-way automated communication interventions can be effective 
and acceptable to patients with a wide range of LTCs. Most were 
focused on a single LTC and more research is needed to explore 
how multi-morbidity can be addressed. Future research also needs 
more holistic evaluation of such interventions to consider 
effectiveness and acceptability to patients and professionals. 
 
 
3mT018 
 
Safe medication use in patients with (risk of) 
impaired renal function: development and 
implementation of a new pharmaceutical care 
service 
 
Ellen S. KOSTER, Daphne PHILBERT, Marcel L. BOUVY 
Background 
In the Netherlands, there are approximately 1 million people with 
impaired renal function. Early detection and treatment of impaired 
renal function is important to prevent drug related problems and 
adverse events. However, to date, renal function of patients using 
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risk medication is not systematically monitored and when it is this 
information is not always exchanged between different care 
providers. The community pharmacist could play an important role 
in monitoring patients with risk of impaired renal function and 
thereby preventing medication related problems.   
Purpose 
Our aim is to evaluate the effect of a new pharmaceutical care 
service to improve safe medication use in patients with (risk of) 
impaired renal function.  
Methods 
In this project a new care intervention - the Kidney Check & 
Interview - is developed (manual for risk stratification, verification 
of actual risk and guideline for patient counseling), implemented 
and evaluated in 50 Dutch community pharmacies. We focus on 
patients with a known or increased risk of reduced kidney 
function:> 65 years, diabetes and / or cardiovascular disease. The 
first step in intervention development is consultation of an expert 
panel (internist, nephrologist, general practitioner, 3 community 
pharmacists and an outpatient pharmacist). 
Results 
Experts indicate that especially good collaboration with other 
healthcare providers, primarily the general practitioner, is of great 
importance. Pharmacists must also be well-trained. 
Implementation of a Point-of-Care test in the pharmacy has no 
priority, focus should be on exchange of patient data. These results 
will be used to develop the intervention.  
Conclusion 
The process of medication control for patients with (risk of) 
impaired renal function is far from optimal and varies between 
pharmacies. This project contributes to the active detection and 
monitoring of patients with reduced kidney function by public 
pharmacists. With proven improved care, this project may give rise 
to scaling the care intervention to national implementation. 
 
 
3mT019 
 
Exploring deprescribing opportunities for 
community pharmacists 
 
Clara KORENVAIN, Linda MACKEIGAN, Katie DAINTY,  
Sara J. GUILCHER, Lisa MCCARTHY 
Background 
The process of stopping medications, or deprescribing, is gaining 
increasing attention as a way to reduce the use of harmful or 
unnecessary medications. However, deprescribing is challenging 
for patients and prescribers. Community pharmacists can 
potentially ease some of these challenges through involvement in 
the process because they likely encounter deprescribing 
opportunities regularly and have the medication expertise to 
address them. However, few studies directly describe their actual 
or potential roles in deprescribing.  
Purpose 
To explore community pharmacists’ current involvement with 
deprescribing in Ontario, Canada, and potential opportunities for 
enhancing their involvement. Findings will inform the design of 
interventions to enhance community pharmacists’ participation in 
deprescribing.   
Methods 
We conducted qualitative telephone interviews with a 
convenience sample of 17 Ontario community pharmacists 
selected to achieve variability in years of experience, pharmacy 
position (staff/management), and geographic location 
(urban/rural). Concepts from the Behavior Change Wheel 
framework from implementation science informed interview topics 
and initial coding. Three interview transcripts were coded 
independently by four investigators to develop a codebook, and 
the remainder coded by one investigator, who then used thematic 
analysis to generate preliminary themes.   
Results 
Participants were involved with deprescribing in their practices to 
variable extents. Preliminary themes are: (1) pharmacists’ 
conceptualization of deprescribing affects how they identify and 
act on deprescribing opportunities; (2) tensions between 
pharmacists’ health professional and business roles challenge their 
ability to prioritize deprescribing in daily practice; and (3) 
suboptimal access to patients’ medical information from 
prescribers influences pharmacists’ willingness to assume 
responsibility for deprescribing.   
Conclusions 
Preliminary findings support recommendations for optimizing 
community pharmacists’ current roles in deprescribing by focusing 
pharmacists’ time on steps in the process that they can contribute 
to most efficiently and effectively (such as monitoring). Future 
research is warranted to examine strategies to expand their roles, 
such as by eliciting prescriber support and engagement.  
 
 
3mT020 
 
Implementation science to promote the 
contribution of the Swiss community pharmacists in 
chronic care management 
 
Noura BAWAB, Aurélien GEORGES, Christophe ROSSIER, 
Clémence PERRAUDIN, Olivier BUGNON 
Background 
In 2014, the Swiss Health Authorities recognized the benefit to 
expand the role of the pharmacists in primary care setting, and 
notably in person-centred, interprofessional practice models. For 
the first time, they acknowledged the need not only to assess the 
effectiveness of a program, but also to formulate 
recommendations for favourable framework conditions to its 
implementation. In this context, this PhD illustrates the use of the 
implementation science to support the development and 
dissemination of effective and sustainable collaborative pharmacy 
services in chronic care management. 
Purpose 
To assess the implementation process and the effectiveness of a 
pharmacist-led, interprofessional chronic patients support 
program (medication therapy management, electronic adherence 
monitoring, regular motivational interviews and feedback reports 
to physicians) for type 2 diabetics taking at least one oral 
medication. 
Methods 
An hybrid implementation-effectiveness analysis using 1) data 
from a prospective, multicentric, observational study, 2) the 
theoretical ""Framework for the Implementation of Services in 
Pharmacy"", 3) a mixed qualitative and quantitative method. 
Outcomes are assessed at each phase of the implementation 
process: exploration, preparation, operation, sustainability. 
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Results 
Twenty-seven of forty-one volunteer pharmacies delivered the 
program to 212 patients. Mean inclusion per pharmacy was 8 ± 6 
patients [range: 1-29]. Nine pharmacies reached the target of 10 
patients. Main influencing factors identified are pharmacists' skills, 
the pharmacy owner support, the interprofessional local 
networking and the program profitability. 
Conclusions 
The current evaluation of the implementation phases will 
determine which priority framework conditions (pre- and post-
graduate training, remuneration, regulations, etc.) are needed to 
successfully transform the traditional community pharmacy 
practice towards the delivery of person-centred and collaborative 
pharmacy services. 
 
 
3mT021 
 
Pharmacist-led medication review with follow-up on 
elderly patients in cardiovascular disease risk factors 
using polypharmacy: a pilot study 
 
Antonio AHUMADA, Francisco MARTÍNEZ MARDONES, 
Victoria GARCÍA-CÁRDENAS, Shalom I. BENRIMOJ,  
Cristian PLAZA-PLAZA 
Background 
It is estimated that 65% of older adults have high risk of developing 
Cardiovascular Diseases (CVD) having uncontrolled risk factors. 
These patients often use polypharmacy and only 30% of them are 
adherent to their medications, causing Negative Outcomes 
associated with Medications (NOMs). Care provided by 
pharmacists is one of the proposed solutions to address this. 
Pharmacist-led Medication Review with Follow-up (MRF) is a cost-
effective strategy. Nevertheless, there is no Chilean data of to 
support the implementation of this pharmacy service. 
Purpose 
The aim of this study was to evaluate the feasibility of 
implementation of MRF in Chilean primary care. 
Methods 
A pilot study was carried out in eight health centres (4 in each 
arm). For 3 months, the intervention arm used the Dader method 
of MRF adapted to the Chilean primary care. Inclusion criteria were 
adults older than 65 years old, using polypharmacy and included in 
the CVD Chilean program. Clinical outcomes for CVD risk factors 
were assessed like systolic and diastolic blood pressure (SBP and 
DBP respectively), HbA1c, fasting glucose, total cholesterol (TC), 
LDL cholesterol, triglycerides, among others. In addition, 
medication adherence, barriers, and facilitators for providing the 
service were evaluated. 
Results 
66 patients were recruited. Reductions were found on SBP 
(11.21mmHg), DBP (6.49mmHg), TC (57.57mg/dL), LDL cholesterol 
(36.05mg/dL) and triglycerides (93.73mg/dL). Main barriers were 
lack of pharmacists experience, of a counseling area, of time to 
provide the service, among others. 
Conclusions 
Through this pilot study we could identify barriers for the provision 
of MRF. Also, this service could have a positive impact in the 
Chilean context. These results will be used to improve the 
procedures for the main study. 
 
 
3mT022 
 
Development, dissemination and evaluation of two 
pharmacy-based patient support programs 
(fingolimod ; immunoglobulin) enhancing patient 
safety and medication adherence 
 
Aline BOURDIN, Jérôme BERGER, Olivier BUGNON 
Background 
The constant demographic, societal, health technologies and 
medicine evolution, as well as the increasing prevalence of chronic 
diseases in a still too fragmented health system, calls for an urgent 
and fundamental change. WHO addressed this call in 2016, 
emphasizing the need of reengineering health systems toward 
more people-centred and integrated health services. Patient 
Support Programs (PSPs) are innovative models of care responding 
to this WHO global strategy. 
Purpose 
To develop, disseminate and evaluate two pharmacy-based PSPs 
supporting patient safety and medication adherence. 
Methods 
One PSP was tailored for fingolimod, first oral drug for Multiple 
Sclerosis (MS) but associated with safety issues. It combines 
regular motivational interviews, electronic longitudinal adherence 
monitoring and pharmacovigilance activities, carried out in 
collaborative practice between pharmacist, neurologist and MS-
nurse. A secured web platform and a trained pharmacy network 
enable the Fingolimod-PSP (F-PSP) dissemination. The other PSP is 
addressed to patients with subcutaneous self-infusion of 
immunoglobulin (SCIg) requiring a specific therapeutic education. 
It was designed in three interprofessional steps: inclusion in 
coordination with the physician, structured education together 
with a nurse at patients’ home and long term-support with phone 
calls and annual administrations under supervision. 
Results 
Seventy patients have voluntarily joined the F-PSP (2013-2017). 
Early results showed a high medication adherence among these 
patients. Moreover, in a qualitative study performed in 2017 
patients reported a positive experience with the F-PSP. They 
considered it as a comprehensive and complementary approach to 
their medical care. The SCIg-PSP has involved 13 patients since 
2012. An economic evaluation demonstrated that the SCIg-PSP is 
cost-effective, compared to the hospital-based intravenous 
infusions. 
Conclusions 
These PSPs are intended to be generic models for any complex 
medication therapies, transposable as advanced pharmacy 
services. 
 
 
3mT023 
 
Effects of a clinical medication review focused on 
personal goals in older patients with polypharmacy; 
results of the DREAMeR study a randomized 
controlled trial 
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Sanne VERDOORN, Henk-Frans KWINT, Jeanet W. BLOM, 
Jacobijn GUSSEKLOO, Marcel L. BOUVY 
Background 
A clinical medication review (CMR) can reduce drug-related 
problems (DRPs). There is little evidence for effects on clinical 
outcomes. To improve quality of life a CMR could be more focused 
on health-related complaints and wishes of older persons.  
Purpose 
The aim is to investigate the effects of a CMR, focused on personal 
goals, on quality of life and health-related complaints in older 
patients with polypharmacy. 
Methods 
The DREAMeR-study was a randomized controlled trial performed 
in 35 community pharmacies located throughout the Netherlands. 
629 persons aged 70 years and over using seven or more chronic 
drugs were randomly assigned to usual care or to receive a CMR. 
They were measured after three and six months. Main outcome 
measures were: health-related quality of life (HR-QoL) and number 
of health-related complaints. HR-QoL was measured with EQ-5D-5L 
(utility) and EQ-VAS. Complaints were defined as number of 
complaints independent of severity and number of complaints 
with impact on daily life (VAS-score ≥5 and influence on daily life 
on 5-point Likert scale: moderate-severe). Also the number of 
drugs in use were measured. Effects were analysed with linear 
mixed model analysis.  
Results 
Over six months, the utility measured with EQ-5D-5L remained 
equal between both groups (β=-0.0011; p=0.90) and the total 
number of complaints did not change (β=-0.14; p=0.12). The self-
rated HR-QoL (EQ-VAS) increased in the intervention group (β=1.7; 
p<0.01) compared to control group and the number of complaints 
with impact on daily life decreased in the intervention group (β=-
0.17; p=0.029). The number of drugs in use decreased over time in 
the intervention group (β=-0.054 per month; p<0.05).  
Conclusions 
A CMR focused on personal goals, improves the self-rated quality 
of life of older patients with polypharmacy and reduces the 
number of health-related complaints with impact on daily life, 
while the number of drugs in use decreases. 
 
 
